Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10842397 | 1.00 | LDHA (0.56) | LDHACA2SIGMAR1KDM4EATM | |
| SCHEMBL16929911 | 0.90 | SIGMAR1 (0.55) | LDHACA2SIGMAR1KDM4E | |
| SCHEMBL16929861 | 0.88 | SIGMAR1 (0.63) | LDHASIGMAR1PPARDPPARA | |
| SCHEMBL16930229 | 0.86 | SIGMAR1 (0.69) | LDHACA2SIGMAR1KDM4EATM | |
| SCHEMBL16930335 | 0.86 | SIGMAR1 (0.56) | LDHACA2SIGMAR1KDM4EATM | |
| SCHEMBL10437147 | 0.86 | KDM4E (0.58) | LDHACA2SIGMAR1KDM4EATM | |
| SCHEMBL16973665 | 0.85 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL16930066 | 0.85 | MAPT (0.47) | SIGMAR1KDM4EALDH1A1SLC6A4 | |
| SCHEMBL16929994 | 0.85 | TAAR1 (0.50) | LDHASIGMAR1SLC6A4 | |
| SCHEMBL7298435 | 0.84 | LDHA (0.58) | LDHACA2SIGMAR1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143020-B1 | DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3143020-B1 | DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| CN-106459032-B | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2019-04-05 | — | — | CN | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-9920049-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920049-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920049-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2015173164-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| US-5840981-A | CATALYTICALLY HYDROGENATING 3,4-DIMETHOXYPHENYLACETONITRILE WITH A METHYLAMINE | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| WO-1997038692-A1 | BISINDOLES FOR TREATING PAIN OR NOCICEPTION | ELI LILLY AND COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| US-4581172-A | Substituted pyrimido[6,1-a]isoquinolin-4-ones,pyrimido[6,1-a]benzozepin-4-ones and pyrimido[6,1-a]benzodiazepin-4-ones useful for prevention of thromboses and treating hypertension | HOFFMANN-LA ROCHE INC. (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | LDHA 1933/4885CA2 4881/4885SIGMAR1 1670/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | LDHA 1395/4885CA2 985/4885SIGMAR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.